• Explore /
  • Poster
  • / The efficacy and safety of anti–PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.

The efficacy and safety of anti–PD-1 antibody toripalimab combined with surufatinib in neoadjuvant treatment of locally advanced thyroid cancer: A phase II study.

Abstract Poster

Authors

null

Jiaying Chen

Fudan University Shanghai Cancer Center, Shanghai, China

Jiaying Chen , Qinghai Ji , Yu Wang , Naisi Huang , Jiaqian Hu , Wenjun Wei , Caiping Huang , Qiang Shen , Duanshu Li

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Other Head and Neck Cancer (Salivary, Thyroid)

Clinical Trial Registration Number

NCT04524884

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 6084)

DOI

10.1200/JCO.2022.40.16_suppl.6084

Abstract #

6084

Poster Bd #

76

Abstract Disclosures

Similar Posters

First Author: Naisi Huang

First Author: Dan Liu

First Author: Daisuke Takahari

First Author: Guangwen Yuan